CHINA DASHENG BIOTECH CO - CDBT STOCK NEWS

China Dasheng Biotechnology Co. (CDBT) has been issued 2 Judgements in its favor against Kenneth Maciora and Empire Relations Group, Inc. The judgements have been registered with the Magistrates Court of Queensland. CDBT has terminated the Consulting Agreement with Kenneth Maciora and filed claims for the return of advanced funds. CDBT has entered a Share Exchange Agreement to acquire all outstanding shares in Cycclone Magnetic Engines, Inc., engaged in low carbon emission engines and clean technology solutions.

China Dasheng Biotechnology Co. terminates consulting agreement with Kenneth Maciora, Empire Relations Group

China Dasheng Biotechnology Co. (OTC PINK:CDBT) announces approval for all Cycclone Magnetic Engine related technology and intellectual property to become housed under CDBT. Shareholder meetings held to formalize the bringing together of subsidiaries and intellectual property. CEO spoke about corporate compliance, intellectual property capture, and ongoing operations.

China Dasheng Biotechnology Co. (OTC PINK:CDBT) has expanded its transport operations through its subsidiary Roadbees Transport Pty Ltd. The company has relocated its operations to Yatala, Brisbane, increasing its pallet storage and handling capabilities. CDBT plans to grow its transport division and eventually separate it into a stand-alone entity.

China Dasheng Biotechnology Co. (CDBT) has signed a Share Exchange Agreement to acquire all outstanding shares of Cycclone Magnetic Engines, Inc. (CME). This acquisition consolidates CDBT’s control over CME, providing full ownership of intellectual property, assets, and equipment associated with Cycclone Magnetic Engines. CME, founded in January 2005, specializes in low carbon emission engines and clean technology solutions. The merger will result in a rebranding of CDBT to Cycclone Magnetic Engines, Inc. The integration aims to enhance operational efficiency and reduce greenhouse emissions, reflecting the company's commitment to shareholders and sustainable practices. CDBT's CEO, Micheal Nugent, highlighted the strategic importance of this acquisition in realizing the vision of its founders.

China Dasheng Biotechnology Co. (OTC PINK:CDBT) reported on April 20, 2023, an incident involving embezzlement by former operations manager Cameron James Smith at their transport unit, Roadbees Transport Pty Ltd. In late December 2021, Smith misled clients into depositing funds into his personal accounts by falsely claiming that company accounts were compromised. His actions were flagged within 17 days, leading to a swift investigation.

Queensland Police are now involved, confirming allegations of impropriety. The company emphasized the effectiveness of their accounting systems in detecting suspicious conduct. Additionally, the company is progressing on a share exchange agreement with Cycclone Magnetic Engine Developments, focusing on low carbon emission technologies.

China Dasheng Biotechnology Co. (OTC PINK:CDBT) announced a significant development with its subsidiary, Cycclone Magnetic Engines, securing a work order for the production of the new Y9XM engine.

Manufacturing will take place across three facilities in Australia. The initial target is to produce 50 engines for testing in stationary power applications, particularly for agricultural needs.

The company aims to achieve market certification and compliance for its engines, paving the way for future commercial opportunities. This advancement highlights CDBT's commitment to developing low-carbon emission technologies.

Cycclone Magnetic Engines, formerly China Dasheng Biotechnology Co. (OTC PINK:CDBT), is recognized in Global Business Leaders Magazine's "20 Leading Companies of the Year 2023." This acknowledgment follows the company’s transition into the public market, aiming to overcome prior challenges related to its unproven technology. Under CEO Micheal Nugent’s leadership, the company is focused on designing engines powered by permanent magnets. Despite facing legal hurdles, Cycclone aims to produce 3D models and conduct open testing on new engine prototypes, with a vision for commercial production in the future.

China Dasheng Biotechnology Co. (OTC PINK:CDBT) is set to be renamed Cycclone Magnetic Engine Developments, Inc. after leasing two industrial properties in Bangalow, New South Wales. This strategic move aims to bolster their component development operations for the new Cycclone Y9MX engine, featuring advanced technology like a staggered crank and 18 powerful magnets. The project will also see the filing of patents, which had been delayed due to various challenges. Furthermore, efforts to close a merger with a custodian rescue company are ongoing, and the company is preparing to return to full reporting as an audited filer.